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37.6 mm and the mean ulcer size was 10.3 cm 2 . C-reactive 
protein (CRP) was elevated in 73.2%; leukocytosis was pres-
ent in 58.9% and neutrophilia in 50.9%. At least 1 associated 
comorbidity was present in 85% (the most prominent being 
cardiovascular disease). The most often used systemic treat-
ments were steroids (68.3%), cyclosporine A (31.7%), dap-
sone (31.7%), and infliximab (13.3%), and the most often 
used topicals were tacrolimus 0.1% (48.3%) and corticoste-
roids (35%). PG healed completely at discharge in 50.8%. The 
average time to diagnosis was 8 months, and the mean dura-
tion to healing was 7.1 months.  Conclusion: PG is a difficult-
to-diagnose skin disease. Here, markers for inflammation 
such as CRP, leukocytosis, and neutrophilia were elevated in 
50–73% of the PG patients.   © 2017 S. Karger AG, Basel 
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 Abstract 
 Background/Aim: Pyoderma gangrenosum (PG) is a rare, 
neutrophilic dermatosis often associated with an underlying 
disease, and clinical data or larger studies are rare.  Methods: 
In this retrospective study, disease characteristics, clinical 
manifestations, and treatment response were evaluated in a 
Swiss cohort of PG patients.  Results: In participating centers, 
34 cases (21 females) of PG were analyzed based on clinical 
and histological presentation between 2002 and 2012. The 
mean age at diagnosis was 61.2 years; 50% of the patients 
experienced only 1 episode of PG. In 13 cases (out of 20), re-
currences occurred during PG therapy; 64.1% showed only 1 
lesion simultaneously. The predominant localization was the 
lower limb (67%). The lesions were disseminated in 26.6%. At 
the time of diagnosis or recurrence, the mean diameter was 
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 Introduction 
 Pyoderma gangrenosum (PG) is a rare, idiopathic, 
neutrophilic dermatosis presenting with sterile and pain-
ful skin ulcerations and very rarely extracutaneous in-
volvement of lung, bone, liver, spleen, myocardium, 
central nervous system, and cornea  [1, 2] . The exact 
pathomechanism remains largely unknown. PG onset 
has been described in association with different therapies, 
comorbidities, trauma, or surgery (pathergy phenome-
non), which is present in up to 25% of cases  [3–6] . Ge-
netic analysis showing mutations of autoinflammatory 
genes like MEFV, NLRP3, NLRP12, NOD2, LPIN2, and 
PSTPIP1 as well as overexpression of inflammatory 
cytokines like IL-1β, IL-17, IL-8, CXCL 1/2/3/16, and 
RANTES suggests that PG is an autoinflammatory dis-
ease  [7, 8] .
 PG can be classified into (I) a mild pustular form, (II) 
a rapidly progressive, purulent, ulcerative PG, (III) a 
superficial, vegetative form, and (IV) a bullous form in 
which bullae occur before the development of ulceration 
 [5, 9] . Additionally, 6 rare variants have been reported: 
posttraumatic and postoperative, peristomal, genital, ex-
tracutaneous neutrophilic disease, pyostomatitis vege-
tans, and PG of infancy and childhood  [10–12] . 
 An underlying systemic disease is reported in up to 
75% of cases, including inflammatory bowel disease 
(IBD), endocrine disorders including diabetes, hemato-
logical, autoimmune-mediated, or rheumatological dis-
orders, and nonhematological malignant diseases  [4, 13, 
14] . For IBD it could be shown that PG is not necessarily 
related to the activity of the underlying disease  [15] .
 PG is often misdiagnosed at first manifestation and 
remains a diagnosis of exclusion. The broad differential 
diagnosis of ulcerative lesions, especially infectious dis-
eases, must be ruled out. Histology is not specific but 
shows a sterile neutrophilic infiltrate, mixed inflamma-
tion, or lymphocytic vasculitis, which may give a hint 
towards PG. Su et al.  [16] and von den Driesch  [17] sug-
gested criteria for PG diagnosis. Two major and at least 
2 minor criteria have to be fulfilled. The criteria of Su et 
al.  [16] are as follows: major criteria: (1) rapid progres-
sion of a painful, necrotic cutaneous ulcer with irregular 
violaceous undermined border, and (2) exclusion of rel-
evant differential diagnosis; minor criteria include (a) 
pathergy in the patient’s history or cribriform scarring 
upon clinical examination, (b) presence of associated 
disease, (c) histology with sterile dermal neutrophilia, 
mixed inflammation, or lymphocytic vasculitis, and (d) 
response to systemic steroid therapy. The criteria of von 
den Driesch are the following: major criteria: (1) occur-
rence of a primary sterile, chronic ulceration, typically 
with violaceous undermined borders, and (2) exclusion 
of relevant differential diagnosis; minor criteria include 
(a) histology from borders of the ulceration revealing 
dermal neutrophilia with vasculitis and immunoglobulin 
deposits or complement factor deposits in the vessels, (b) 
presence of associated disease, and (c) response to sys-
temic immunosuppressive therapy, with little or no re-
sponse to conventional external ulcer therapies. 
 The most frequently reported topical treatments in-
clude tacrolimus and topical and intralesional corticoste-
roids. Nicotine cream and pimecrolimus are also often 
used and occasionally sodium cromoglycate  [18, 19] . 
Other topicals have also been reported to be effective but 
the level of evidence is low: intralesional cyclosporine A, 
potassium iodide, nitrogen mustard, platelet-derived 
growth factor, recombinant human epidermal growth 
factor, hyperbaric oxygen, and surgical repair by graft or 
flap. In a case series of 6 patients it was found that the 
topical coagulation factor XIII also exerts beneficial ef-
fects on the tissue regeneration and wound healing in re-
calcitrant PG  [20] . Systemically different schemes have 
been suggested – widely accepted are corticosteroids +/– 
cyclosporine A as 1st-line therapy  [21] and dapsone as 
2nd-line therapy. Other treatments including TNF-α in-
hibitors (infliximab, adalimumab, etanercept), thalido-
mide, tacrolimus, cyclophosphamide, azathioprine, my-
cophenolate mofetil, clofazimine, IVIG, GM-CSF, colchi-
cine, and methotrexate have been reported as 3rd-line 
therapies  [2, 5, 6, 14, 15, 22–24] . Recently, we showed that 
canakinumab (monoclonal anti-IL-1b antibody) is effec-
tive in steroid-refractory PG as well as we and others for 
ustekinumab (anti-IL-12/IL-23 monoclonal antibody) 
 [25–27] . In addition of the above therapies, control of the 
underlying associated disease could have a positive effect 
on the PG course  [15] .
 In this retrospective study, we evaluated the disease 
characteristics, clinical manifestations, laboratory values, 
and treatment outcomes of a cohort of PG patients from 
2 major hospitals in Switzerland between January 2002 
and December 2012. 
 Material and Methods 
 For further details, see the supplementary material (see www.
karger.com/10.1159/000481432 for all online suppl. material)  [16, 
17] ( Fig. 1 ).
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 Results 
 Between 2002 and 2012, a total of 34 cases of diagnosed 
PG (14 from University Hospital Zurich, 5 from the pri-
vate practice of Prof. Werner Kempf, and 15 from Kan-
tonsspital St. Gallen) were included in the study. Of the 
34 patients, 21 were female (61.8%, female:male ratio 1.6: 
 1), and the mean age at time of diagnosis was 61.2 years 
(range, 18–86 years). The mean BMI was 24.1 (range, 
17.4–32.1). Nicotine and alcohol consumption was docu-
mented in 20.6 and 11.8% of patients, respectively ( Ta-
ble 1 ).
 In total, 60 admissions of PG with a mean number of 
1.9 lesions per patient (range, 1–7) were documented, 
with a female predominance of 2.2 versus 1.5 admissions. 
Of the 60 admissions, 17 (50% of patients) were due to 
only 1 flare. In 10 admissions follow-up information was 
not available. The remaining patients showed a first epi-
sode (13 admissions) with repetitive recurrent disease ei-
ther during (13 admissions) or without therapy (7 admis-
sions). Pathergy phenomenon was reported in 16 patients 
(47%) ( Fig.  2 ). Only 1 lesion was present in 61.7% (37 
admissions), 2–4 lesions in 28.3% (17 admissions), 5–7 
lesions in 8.3% (5 admissions), and more than 7 lesions 
Suspicious diagnosis
of PG
(n = 179)
Clinically consistent
with PG*
(n = 38)
Clinically and
histologically not
consistent with PG*:
excluded
(n = 141)
Histology consistent
with PG
(n = 25)
Histology unspecific
for PG
(n = 9)
Other histological
diagnosis
(n = 4)
ଶ First episode
ଶ Recurrence during PG therapy
ଶ Recurrence without PG therapy
ଶ Unknown
ଶ Single episode
17%
11%
22%
22%
28%
ଶ Lower limb (lower leg)
ଶ Lower limb (upper leg)
ଶ Upper limb
ଶ Face
ଶ Torso
4%
5%
12% 55%
24%
 Table 1.  Demographics: patient characteristics
Total number of patients, n (%) 34 (100)
Male, n (%) 13 (38.2)
Female, n (%) 21 (61.8)
Gender ratio (F:M) 1.6:1  
Mean age (±SD), years 65.9 ± 18.5  
Mean age at manifestation (±SD), years 61.2 ± 17.8  
Mean height, m 1.7  
Mean weight, kg 67  
Mean BMI 24.1  
Smoking (yes), n (%) 7 (20.6)
Alcohol (yes), n (%) 4 (11.8)
 Demographic analysis of the pyoderma gangrenosum cohort.
 Fig. 1. Flowchart of Materials and Meth-
ods. Decision tree of pyoderma gangreno-
sum (PG) inclusion.  *  According to the cri-
teria of Su et al.  [16] .  
 Fig. 2. Recurrence of disease. Disease course divided into patients 
with only a single pyoderma gangrenosum (PG) episode, recurrent 
disease with first episodes, and variable recurrences by onset dur-
ing or without PG therapy.  
 Fig. 3. Pyoderma gangrenosum lesion localization by body area. 
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in 1.7% (1 admission). The average time to diagnosis was 
8.1 months (±18.5 months, range, 0–88 months).
 At the time of diagnosis or recurrence, information 
was available in 56 admissions about lesion size, with a 
mean diameter of 37.6 mm and a mean ulcer size of 10.3 
cm 2 (total 67 lesions): 2 lesions (3%) measured under 10 
mm, 36 (53.7%) 10–30 mm, 22 (32.8%) 31–60 mm, and 
7 (10.4%) over 60 mm. 
 In total, 115 PG lesions were recorded, the most com-
mon site being the lower limb (67.0%: 54.8% on the low-
er leg and 12.2% on the thigh) followed by the upper body 
(24.3%), the upper limbs (5.2%), and the face (3.5%) 
( Fig. 3 ). In 26.6% of cases PG occurred simultaneously in 
at least 2 separate anatomical sites. Postoperatively, 8 le-
sions appeared, of which 5 occurred after cesarean sec-
tion. Eight PG lesions (7%, 4 females with 7 episodes and 
1 male) developed posttraumatically following acupunc-
ture, punch biopsy, insect bite, or direct accidental blunt 
trauma. 
 C-reactive protein (CRP) values were available in 41 
admissions, with 73.2% having elevated CRP values: 15 
had a value of 5 mg/L or lower (26.8%, normal), 22 be-
tween 5 and 40 mg/L (39.3%), 11 between 41 and 200 
mg/L (19.6%), and 8 over 200 mg/L (14.3%) (reference 
value <5 mg/L). Leukocyte counts were available in 41 
admissions, with 58.9% having leukocytosis: 41.1% be-
tween 3.5 and 9.6 × 10 9 /L (normal), 48.2% between 9.7 
and 20 × 10 9 /L, and 6 over 20 × 10 9 /L, with a mean leu-
kocyte concentration of 10.5 × 10 9 /L (reference value 3.5–
9.6 × 10 9 /L). Neutrophil counts were available in 41 ad-
missions, with 50.9% showing neutrophilia (reference 
value 1.4–8.0 × 10 9 /L): 49.1% between 1.4 and 8.0 × 10 9 /L 
(normal), 38.6% between 8.1 and 20 × 10 9 /L, and 12.3% 
over 20 × 10 9 /L. Neutropenia or leukopenia were not 
found in any patient ( Table 2 ).
 Comorbidity was found in 29 of 34 patients (85%) ( Ta-
ble 3 ). Cardiovascular diseases showed the highest preva-
lence and were observed in 79.4% of patients. Hemato-
logical diseases were present in 23.5%, autoimmune or 
inflammatory diseases in 17.6%, IBD in 14.7%, rheuma-
tological diseases in 35.3%, nonhematological malignan-
cies in 14.7% (2 breast, 1 ovarian, 1 prostate cancer, and 
1 precancerous cervical lesion), pulmonary disease in 
8.8%, allergies in 20.6%, renal insufficiency in 20.6%, psy-
chiatric diseases in 8.8%, and chronic infections (like sta-
tus posthepatitis B or C/others) in 8.8% of patients. More 
than one comorbidity was seen in 15 patients (44.1%). No 
associated comorbidity was seen in 5 patients (15%). 
None of our patients showed extracutaneous PG involve-
ment. 
 Tacrolimus 0.1% ointment was used in 48.3% of all 
admissions, topical antimicrobial agents were used in 
CRP (Ref. <5 mg/L)
<5 mg/L 15 (26.8)
5 – 40 mg/L 22 (39.3)
41 – 200 mg/L 11 (19.6)
>200 mg/L
Available CRP values on admission, n (%)
8 (14.3)
56 (100)
Median CRP (±SD), mg/L 14.5 ± 92.5
Leukocytes (Ref. 3.0 – 9.6 × 109/L)
<3.5 × 109/L 0 (0.0)
3.5 – 9.6 × 109/L 23 (41.1)
9.7 – 20 × 109/L
>20 × 109/L
27 (48.2)
6 (10.7)
Available leukocyte counts on admission, n (%) 56 (100)
Median leukocytes (±SD), × 109/L 10.5 ± 13.2
Neutrophils (Ref. 1.4 – 8.0 × 109/L)
<1.4 × 109/L 0 (0.0)
1.4 – 8.0 × 109/L 28 (49.1)
8.1 – 20 × 109/L 22 (38.6)
>20 × 109/L
Available neutrophil counts on admission, n (%)
7 (12.3)
57 (100)
Median neutrophils (±SD), × 109/L 8.36 ± 15.1
 Data are presented as number of admissions (%) unless otherwise indicated.
 Table 2.  Laboratory values (CRP, 
leukocytes, neutrophils) of the pyoderma 
gangrenosum cohort
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 Table 3.  Comorbidities (n = 34 patients)
Total Age 15 – 54 Age 55 – 74  Age 75+
counts % counts % counts % coun ts %
Inflammatory bowel disease  5 14.7 2 5.9 0 0.0 3 8.8
 Crohn disease 3 8.8 2 5.9 0 0.0 1 2.9
 Colitis indeterminata 1 2.9 0 0.0 0 0.0 1 2.9
 Colitis ulcerosa 1 2.9 0 0.0 0 0.0 1 2.9
Cardiovascular diseases  27 79.4 2 5.9 5 14.7 19 55.9
 Arterial hypertension 10 29.4 0 0.0 1 2.9 9 26.5
 Peripheral obstructive arterial disease 2 5.9 0 0.0 1 2.9 1 2.9
 Hypertensive heart disease 4 11.8 0 0.0 0 0.0 4 11.8
 Myocardial infarction 2 5.9 0 0.0 0 0.0 2 5.9
 Cardiopathy of unknown origin 1 2.9 0 0.0 1 2.9 0 0.0
 Cerebrovascular infarction 1 2.9 0 0.0 1 2.9 0 0.0
 Diabetes mellitus 3 8.8 0 0.0 0 0.0 3 8.8
 Thrombosis 3 8.8 2 5.9 0 0.0 0 0.0
 Metabolic syndrome 1 2.9 0 0.0 1 2.9 0 0.0
Rheumatological conditions  12 35.3 1 2.9 2 5.9 7 20.6
 Rheumatoid arthritis 1 2.9 0 0.0 0 0.0 1 2.9
 Polymyalgia rheumatica 1 2.9 0 0.0 0 0.0 1 2.9
 Sclerodermia 1 2.9 0 0.0 1 2.9 0 0.0
 Arthralgia/others 5 14.7 0 0.0 1 2.9 3 8.8
 Osteopenia/porosis 4 11.8 1 2.9 0 0.0 2 5.9
Hematological disorder  8 23.5 1 2.9 3 8.8 4 11.8
 MGUS 3 8.8 1 2.9 1 2.9 1 2.9
 Waldenström disease 1 2.9 0 0.0 0 0.0 1 2.9
 Megaloblastic macrocytic anemia 2 5.9 0 0.0 1 2.9 1 2.9
 Spherocytosis 1 2.9 0 0.0 1 2.9 0 0.0
 Lymphoplasmacytic B-cell lymphoma 1 2.9 0 0.0 0 0.0 1 2.9
Inflammatory/autoimmune mediated conditions 6 17.6 1 2.9 3 8.8 2 5.9
 Psoriasis vulgaris 2 5.9 1 2.9 0 0.0 1 2.9
 Antiphospholipid syndrome 2 5.9 0 0.0 1 2.9 1 2.9
 Leukocytoclastic vasculitis 1 2.9 0 0.0 1 2.9 0 0.0
 Hypothyreosis Hashimoto 1 2.9 0 0.0 1 2.9 0 0.0
Malignancy – nonhematological 5 14.7 1 2.9 2 5.9 2 5.9
COPD  3 8.8 0 0.0 0 0.0 3 8.8
Allergies  7 20.6 3 8.8 1 2.9 2 5.9
Renal insufficiency  7 20.6 0 0.0 2 5.9 5 14.7
Psychiatric diagnosis  3 8.8 1 2.9 0 0.0 1 2.9
Hepatitis B/C, other  3 8.8 1 2.9 2 5.9 0 0.0
Multiple comorbidities  15 44.1 2 5.9 4 11.8 9 26.5
Comorbidities by age (15 – 54, 55 – 74, 75+ years) and group (inflammatory bowel disease, cardiovascular, rheumatological, hemato-
logical, inflammatory/autoimmune, and others).
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50%, and topical or intralesional steroids were applied in 
35%. Overall, 68.3% of patients received systemic ste-
roids, 80% of which were immunomodulatory agents, 
among them being cyclosporine A (31.7%), dapsone 
(31.7%), infliximab (13.3%), azathioprine or mesalazine 
(8.3%), and canakinumab (6.7%) ( Table 4 ). Overlapping 
treatment indications for PG and, for example, underly-
ing IBD, as well as contraindications for PG treatments 
like TNF inhibitors, were taken into account. Side effects 
due to systemic therapy were reported in 14 patients 
(41.2%; online suppl. Table 1). A surgical procedure was 
performed in 27.9% of all admissions (17 patients: 4 de-
bridements, 4 debridements + VAC therapy, 2 debride-
ments + Epidex ® application, and 7 debridements + split-
thickness skin graft transplantations). Systemic cortico-
steroids or immunomodulatory therapy were concom-
itantly used in 35.3% of the surgical procedures (no ad-
ditional therapy in 23.5%, unknown in 41.2%). 
 Table 4.  Topical and systemic treatments
Admissions
n %
Topical/intralesional steroids Total 21 35.0
Topical antimicrobials Octenidindihydrochloride 7 11.7
 Fusidic acid 6 10.0
 Chloramine T 6 10.0
 Others 11 18.3
 Total 30 50.0
Topical immunosuppressants Tacrolimus 0.1% 29 48.3
 Infliximab drops 1 1.7
 Total 30 50.0
Other topicals Hyaluronic acid (2 mg/g)/sulfadiazine (20 mg/g) 5 8.3
 Sodium alginate 5 8.3
 Clostridiopeptidase A 4 6.7
 Others 3 5.0
Systemic steroids (oral/i.v.) Total 41 68.3
Systemic immunosuppressants Cyclosporine A 19 31.7
 Azathioprine 5 8.3
 Infliximab 8 13.3
 Etanercept 2 3.3
 Adalimumab 1 1.7
 Canakinumab 4 6.7
 Tacrolimus 3 5.0
 Cyclophosphamide 3 5.0
 Methotrexate 2 3.3
 Mycophenolate mofetil 1 1.7
 Total 48 80.0
Systemic antimicrobials Dapsone 19 31.7
 Clindamycin 5 8.3
 Others 6 10.0
 Total 30 50.0
Other systemics IVIG 2 3.3
 Mesalazine 5 8.3
 IVIG, intravenous immunoglobulins.
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 In 50.8% of all admissions (61 admissions in total) the 
PG healed completely until discharge from the hospital, 
in 47.5% a PG lesion was still present at discharge, and 
1 patient (1.7%) died due to  Pseudomonas aeruginosa 
sepsis. The mean time to complete ulcer healing was 7.1 
months (range, 1–30 months) according to healed PG un-
til discharge. If, when, and how PG healed in nonhospital 
settings cannot be evaluated due to nonavailable data. In 
detail, 21 patients (61.8%) received a combination treat-
ment with topicals and systemics at least on one occasion; 
46% of the completely resolved PG lesions had been treat-
ed with topical steroids, 46% with tacrolimus 0.1% oint-
ment, and 6.6% with intralesional steroids. In cases which 
resulted in complete resolution, systemic steroids was the 
therapy used in 68.8%, cyclosporine A in 29.5%, dapsone 
in 29.5%, infliximab in 16.4%, and surgical intervention 
in 26.2% of cases. 
 Discussion 
 PG is a rare, neutrophil-mediated disease characterized 
by painful skin ulceration. Extracutaneous manifestations 
are very rare and were not present in any of our patients. 
Over a 10-year period, 34 patients with a diagnosis of PG 
fulfilling the criteria suggested by Su et al.  [16] and von 
den Driesch  [17] were reviewed. We found a female pre-
dominance of 1.6: 1, a mean age of manifestation of 61.2 
years, a pathergy phenomenon in 16 patients (47%), and 
the lower limbs as the most frequently affected anatomic 
sites, all of which are consistent with other reports  [3, 4, 
17, 28–34] . The average number of PG flares was 1.9, 
which is lower than previously reported, but women 
showed more frequent recurrences than men (2.2 vs. 1.5) 
 [31] . A single PG lesion was the most frequent clinical pre-
sentation and seen in 37 admissions (61.7%), with a mean 
diameter of 37.6 mm and a mean ulcer size of 10.3 cm 2 ; as 
previously reported, more than half of the lesions had a 
size ranging between 10 and 30 mm in diameter  [31] .
 The mean CRP level of 14.5 mg/L is lower than previ-
ously reported by Saracino et al.  [30] . The mean leucocyte 
and neutrophil counts were 10.5 × 10 9 /L and 8.36 × 10 9 /L, 
respectively. This is the first study reporting evidence of 
elevated CRP, neutrophilia, and leukocytosis in PG pa-
tients, which is indicative of systemic inflammation in PG 
patients, as is more and more suggested in the field  [35] . 
However, potential bias with regard to these data is that, 
retrospectively, a causative or coexistent infection could 
not be fully ruled out. 
 Overall, 79.4% of our patients suffered from associated 
disease, which is in the upper range of previous reports 
(33–79%)  [2, 36] . IBD was present in 14.7% of cases com-
pared to 8.7–34% in previous reports  [28, 36] , and IgA 
MGUS was present in 8.8% compared to 15%  [13] . Inter-
estingly, we found that 79.4% of patients had a cardiovas-
cular disease, with 55.9% of all patients being over 75 
years of age. In the Swiss population, the prevalence of 
arterial hypertension in patients over 75 years ranges 
from 50 to 56% and diabetes ranges from 9 to 18%  [37] . 
Both arterial hypertension and diabetes mellitus were less 
frequent in our patients over 75 years, with 29.4 and 8.8%, 
respectively. In our cohort, cardiovascular comorbidities 
including diabetes mellitus did not appear more fre-
quently than in an age-matched control group. Due to the 
relatively low number of patients in our cohort, it is dif-
ficult to conclude whether there is a relationship between 
PG and this comorbidity or just an unrelated age-typical 
appearance. 
 Prior to study inclusion, we also performed a re-eval-
uation of all 38 biopsies, which led to the exclusion of 3 
patients showing features of Martorell hypertensive is-
chemic leg ulcer (HYTILU) and 1 with morphea. Typical 
characteristics of HYTILU are an ulceration at the lat-
erodorsal lower leg with central black necrosis and purple 
inflamed ulcer borders, typically in patients with arterial 
hypertension (100%) and frequently diabetes mellitus (up 
to 60%) and metabolic syndrome  [38] . If the biopsy taken 
is too small, the chance of visualizing “PG”-like features 
and missing the typical features of HYTILU (subcutane-
ous stenotic arteriolosclerosis in 100% and medial calci-
fication in 71% of cases) is high. A deeper evaluation of 
HYTILU and PG is currently in preparation. 
 In our study, PG was most frequently treated with top-
ical tacrolimus (48.3%) as well as topical (35%) or sys-
temic (68.3%) corticosteroids (prednisone starting be-
tween 60 and 120 mg daily), either as monotherapy or in 
combination with steroid-sparing agents such as cyclo-
sporine A, as reported in previous studies  [2, 15, 24, 28, 
31, 39, 40] . The use of systemic steroids (68.3% of cases) 
was less frequent than previously reported (80%)  [3] . The 
most frequently used biological was infliximab (13.3%). 
In 27.9% of our cases a surgical intervention was per-
formed, but a concomitant immunosuppressive therapy 
was used in only 35.3%. Surgical treatment has been dis-
cussed controversially due to the risk of a pathergy phe-
nomenon. However, more recent studies do not suggest 
elevated pathergy following surgery when combined with 
immunosuppression; on the contrary, up to 60% of pa-
tients show either complete or partial healing  [29, 30] .
 Kolios   et al.
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 In 51% of the PG episodes complete ulcer healing cor-
responding to complete remission occurred within a mean 
time of 7.1 months. In previous studies complete disease 
remission was reported in 69–72% of cases within 3.9–
15.5 months and in 95% within 3 years  [3, 9, 30, 31] . In 
our study, due to the lack of follow-up data, the rate and 
time to complete remission in patients with incompletely 
healed ulcers at discharge is not known. Overall, only 1 
patient with PG died due to  P. aeruginosa sepsis, which 
resulted in a mortality rate of 2.6%. The published average 
mortality rate in PG varies from 6 to 30%  [23, 29, 31] . A 
possible bias might be a shorter follow-up time in our co-
hort compared to published studies. The time to diagnosis 
is often prolonged in PG, and we found 8.1 months to be 
the average time from first manifestation to diagnosis. We 
did not find comparable data from other studies. 
 PG is a rare disease with an estimated incidence of 3–10 
patients per million population per year  [29] . Therefore, 
it is important to improve the diagnostic process in cases 
of unusual skin ulcerations. Early involvement of wound 
specialists and dermatologists is mandatory to evaluate 
PG. Exclusion of other ulcerating skin diseases is neces-
sary before making the diagnosis of PG. Optimized man-
agement with rapid escalation of therapeutic options in 
cases of nonresponse or exacerbation should be consid-
ered  [18] . By showing increased CRP, leukocytosis, and 
neutrophilia in a considerable proportion of our patients, 
an expected but not formally proven aspect of PG was 
identified in this retrospective study. These values have 
not been analyzed together in previous studies. Further 
studies, preferably in larger prospective international reg-
istries, would help to better characterize this rare disease. 
A prospective approach may allow blood and skin sam-
pling as well as performing cytokine profiling with the po-
tential to guide the application of targeted therapies.
 Key Message 
 Markers for inflammation like CRP, leukocytosis, and neutro-
philia were elevated in this pyoderma gangrenosum cohort. The 
average time to diagnosis was 8 months, and the mean duration to 
healing was 7.1 months.
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